AMTI Stock Price, Applied Molecular Transport . Quote, Chart

Market Summary

USD0.26

Delayed

AMTI Stock Price

View Fullscreen

AMTI RSI Chart

AMTI Valuation

Market Cap

10.7M

Price/Earnings (Trailing)

-0.14

Price/Free Cashflow

-0.18

AMTI Price/Sales (Trailing)

AMTI Profitability

Return on Equity

-460.5%

Return on Assets

-373.65%

Free Cashflow Yield

-562.81%

AMTI Fundamentals

AMTI Earnings

Earnings (TTM)

-74.8M

Earnings Growth (Yr)

72.48%

Earnings Growth (Qtr)

59.98%

Breaking Down AMTI Revenue

Last 7 days

-16.1%

Last 30 days

62.5%

Last 90 days

65.6%

Trailing 12 Months

-40.2%

How does AMTI drawdown profile look like?

AMTI Financial Health

Current Ratio

4.99

AMTI Investor Care

Shares Dilution (1Y)

6.15%

Diluted EPS (TTM)

-1.89

Tracking the Latest Insider Buys and Sells of Applied Molecular Transport Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 27, 2023	vandevender aaron	back to issuer	-	-	-212,659	-
Dec 27, 2023	cross shawn	back to issuer	-	-	-545,499	ceo & chair of the board
Dec 27, 2023	mahmood tahir ph.d.	back to issuer	-	-	-3,208,310	-
Dec 27, 2023	hants brandon	back to issuer	-	-	-301,225	cfo
Dec 27, 2023	mahmood tahir ph.d.	back to issuer	-	-	-391,693	-
Dec 27, 2023	epiq capital group, llc	sold	-	-	-8,337,520	-
Dec 27, 2023	mahmood tahir ph.d.	back to issuer	-	-	-484,738	-
Nov 22, 2023	cross shawn	sold	-18,116	0.1635	-110,802	ceo & chair of the board
Nov 22, 2023	hants brandon	sold	-10,054	0.1635	-61,494	cfo
Nov 22, 2023	mahmood tahir ph.d.	sold	-46,784	0.1634	-286,320	-

Which funds bought or sold AMTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	XTX Topco Ltd	sold off	-100	-4,735	-	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-132	-	-%
Jan 31, 2023	Burleson & Company, LLC	reduced	-74.00	-31,045	3,955	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	31,000	31,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	reduced	-41.09	-212,000	99,000	-%
Feb 15, 2022	NEXT Financial Group, Inc	unchanged	-	-1,000	-	-%
Nov 15, 2021	Marshall Wace North America L.P.	added	28.57	-81,000	216,000	-%
Oct 07, 2021	Berman Capital Advisors, LLC	new	-	1,000	1,000	-%

Are Funds Buying or Selling AMTI?

Are funds buying AMTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMTI

No. of Funds

Unveiling Applied Molecular Transport Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	founders fund v management, llc	0.0%	0	SC 13G/A
Jan 05, 2024	epiq capital group, llc	0%	0	SC 13D/A
Feb 09, 2023	mahmood tahir ph.d.	9.69%	3,791,803	SC 13G/A
Feb 03, 2023	mrsny randall ph.d.	9.46%	3,696,089	SC 13G/A
Jul 08, 2022	blackrock inc.	2.5%	961,466	SC 13G
Feb 11, 2022	capital world investors	11.0%	4,225,688	SC 13G/A
Feb 11, 2022	mrsny randall ph.d.	9.46%	3,644,500	SC 13G/A
Feb 11, 2022	mahmood tahir ph.d.	9.45%	3,641,000	SC 13G/A
Feb 04, 2022	blackrock inc.	5.0%	1,939,444	SC 13G
Sep 10, 2021	capital research global investors	4.4%	1,708,437	SC 13G/A

Recent SEC filings of Applied Molecular Transport Inc.

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Applied Molecular Transport Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Applied Molecular Transport Inc. News

Latest updates

Applied Molecular Transport Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-19.8%	20.00	25.00	83.00	107	125	147	182	214	207	224	126	140	158	173	39.00
Current Assets	-19.3%	19.00	23.00	46.00	64.00	80.00	101	133	167	188	206	112	132	149	166	33.00
Cash Equivalents	-19.4%	18.00	22.00	42.00	61.00	76.00	96.00	126	161	152	159	26.00	6.00	11.00	23.00	13.00
Net PPE	-20.5%	0.00	0.00	3.00	8.00	9.00	9.00	9.00	7.00	6.00	7.00	7.00	8.00	8.00	7.00	4.00
Liabilities	-12.5%	4.00	4.00	47.00	47.00	46.00	50.00	54.00	50.00	20.00	16.00	13.00	9.00	9.00	8.00	5.00
Current Liabilities	-1.1%	4.00	4.00	17.00	15.00	14.00	16.00	18.00	14.00	10.00	8.00	9.00	8.00	8.00	7.00	4.00
Shareholder's Equity	-21.3%	16.00	21.00	36.00	61.00	78.00	98.00	128	164	188	208	114	132	149	165	-
Retained Earnings	-1.7%	-418	-411	-393	-365	-343	-318	-282	-239	-209	-183	-159	-139	-120	-103	-72.79
Additional Paid-In Capital	0.6%	434	432	430	427	422	416	410	403	397	392	273	271	269	269	1.00
Shares Outstanding	3.7%	41.00	39.00	39.00	39.00	39.00	39.00	39.00	39.00	37.00	38.00	35.00	23.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	79.6%	-4,399	-21,523	-19,298	-14,816	-19,564	-28,389	-31,131	-22,480	-17,040	-22,141	-20,948	-16,705	-13,581	-14,897	-13,711	-	-	-
Share Based Compensation	38.5%	2,531	1,828	3,223	4,962	5,842	5,590	6,773	5,477	4,937	4,333	1,951	1,078	762	659	557	-	-	-
Cashflow From Investing	-96.9%	45.00	1,471	-7.00	-6.00	-223	-2,406	-1,517	29,112	9,608	41,565	41,921	10,804	2,246	-130,944	8,608	-	-	-
Cashflow From Financing	100.0%	-	-178	-69.00	-53.00	-132	145	-693	734	432	113,829	303	430	-752	163,275	-1,657	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMTI Income Statement

2023-09-30

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 250	$ 18,233	$ 15,796	$ 72,273
General and administrative	7,007	7,281	20,804	28,052
Restructuring, impairment, and related charges	(40)	12	16,832	3,799
Total operating expenses	7,217	25,526	53,432	104,124
Loss from operations	(7,217)	(25,526)	(53,432)	(104,124)
Interest income, net	283	321	1,281	393
Other income (expense), net	(3)	(1)	(36)	5
Net loss	$ (6,937)	$ (25,206)	$ (52,187)	$ (103,726)
Net loss per share, basic (in dollars per share)	$ (0.17)	$ (0.65)	$ (1.32)	$ (2.68)
Net loss per share, diluted (in dollars per share)	$ (0.17)	$ (0.65)	$ (1.32)	$ (2.68)
Weighted-average shares of common stock outstanding, basic (in shares)	39,751,028	38,914,570	39,426,218	38,769,226
Weighted-average shares of common stock outstanding, diluted (in shares)	39,751,028	38,914,570	39,426,218	38,769,226

AMTI Balance Sheet

2023-09-30

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 18,103	$ 61,145
Prepaid expenses	457	2,688
Other current assets	259	186
Total current assets	18,819	64,019
Property and equipment, net	31	8,183
Operating lease right-of-use assets	1,165	33,222
Finance lease right-of-use assets	0	584
Restricted cash	0	916
Other assets	0	522
Total assets	20,015	107,446
Current liabilities:
Accounts payable	161	1,583
Accrued expenses	2,261	8,660
Lease liabilities, operating lease - current	1,353	4,639
Lease liabilities, finance lease - current	0	205
Total current liabilities	3,775	15,087
Lease liabilities, operating lease	0	31,228
Lease liabilities, finance lease	0	49
Other liabilities	0	244
Total liabilities	3,775	46,608
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value, 450,000,000 shares authorized; 40,893,507 and 39,181,801 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	4	4
Additional paid-in capital	434,393	426,804
Accumulated deficit	(418,157)	(365,970)
Total stockholders’ equity	16,240	60,838
Total liabilities and stockholders’ equity	$ 20,015	$ 107,446

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

CEO	Mr. Shawn M. Cross
WEBSITE	appliedmt.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Applied Molecular Transport Inc. Frequently Asked Questions

What is the ticker symbol for Applied Molecular Transport Inc.? What does AMTI stand for in stocks?

AMTI is the stock ticker symbol of Applied Molecular Transport Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Molecular Transport Inc. (AMTI)?

As of Fri Dec 29 2023, market cap of Applied Molecular Transport Inc. is 10.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMTI stock?

You can check AMTI's fair value in chart for subscribers.

What is the fair value of AMTI stock?

You can check AMTI's fair value in chart for subscribers. The fair value of Applied Molecular Transport Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied Molecular Transport Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied Molecular Transport Inc. a good stock to buy?

The fair value guage provides a quick view whether AMTI is over valued or under valued. Whether Applied Molecular Transport Inc. is cheap or expensive depends on the assumptions which impact Applied Molecular Transport Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMTI.